Detail akcie GlycoMimetics online

Business Summary: GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Its drug candidates include Uproleselan, GMI-1687, Galectin Antagonists and GMI-1359. It is developing Uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is a drug candidate that simultaneously targets both E-selectin and a chemokine receptor (CXCR4).
Financial Summary: BRIEF: For the six months ended 30 June 2024, GlycoMimetics Inc revenues was not reported. Net loss increased 12% to $20.8M. Higher net loss reflects researcg and development expense balanc increase from $4.9M to $11.6M (expense), General & Administrative Expe increase of 31% to $7.1M (expense), General and administrative expense increase of 64% to $2.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.30 to -$0.32.